TEST BANK BASIC AND CLINICAL PHARMACOLOGY

14th Edition

By: Bertram Katzung



Test Bank For Basic and Clinical Pharmacology 14th Edition by Bertram Katzung

Table of Contents:
Section I: Basic principles
Chapter 1: Introduction: the nature of drugs & drug development & regulation
Chapter 2: Drug receptors & pharmacodynamics
Chapter 3: Pharmacokinetics & pharmacodynamics: rational dosing & the time course of
drug action
Chapter 4: Drug biotransformation
Chapter 5: Pharmacogenomics
Section II: Autonomic drugs
Chapter 6: Introduction to autonomic pharmacology
Chapter 7: Cholinoceptor-activating & cholinesterase-inhibiting drugs
Chapter 8: Cholinoceptor-blocking drugs
Chapter 9: Adrenoceptor agonists & sympathomimetic drugs
Chapter 10: Adrenoceptor antagonist drugs
Section III: Cardiovascular-renal drugs
Chapter 11: Antihypertensive agents
Chapter 12: Vasodilators & the treatment of angina pectoris
Chapter 13: Drugs used in heart failure
Chapter 14: Agents used in cardiac arrhythmias
Chapter 15: Diuretic agents
Section IV: Drugs with important actions on smooth muscle
Chapter 16: Histamine, serotonin, & the ergot alkaloids
Chapter 17: Vasoactive peptides
Chapter 18: The Eicosanoids: prostaglandins, thromboxanes, leukotrienes, & related
compounds
Chapter 19: Nitric oxide
Chapter 20: Drugs used in asthma
Section V: Drugs that act in the central nervous system
Chapter 21: Introduction to the pharmacology of cns drugs
Chapter 22: Sedative-hypnotic drugs
Chapter 23: The Alcohols
Chapter 24: Antiseizure drugs
Chapter 25: General anesthetics
Chapter 26: Local anesthetics
Chapter 27: Skeletal muscle relaxants
Chapter 28: Pharmacologic management of parkinsonism & other movement disorders
Chapter 29: Antipsychotic agents & lithium
Chapter 30: Antidepressant agents
Chapter 31: Opioid agonists & antagonists
Chapter 32: Drugs of abuse

Section VI: Drugs used to treat diseases of the blood, inflammation, & gout

Chapter 33: Agents used in cytopenias; hematopoietic growth factors

Chapter 34: Drugs used in disorders of coagulation

Chapter 35: Agents used in dyslipidemia

Chapter 36: Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic

drugs, nonopioid analgesics, & drugs used in gout

Section VII: Endocrine drugs

Chapter 37: Hypothalamic & pituitary hormones

Chapter 38: Thyroid & antithyroid drugs

Chapter 39: Adrenocorticosteroids & adrenocortical antagonists

Chapter 40: The Gonadal hormones & inhibitors

Chapter 41: Pancreatic hormones & antidiabetic drugs

Chapter 42: Agents that affect bone mineral homeostasis

Section VIII: Chemotherapeutic drugs

Chapter 43: Beta-lactam & other cell wall- & membrane-active antibiotics

Chapter 44: Tetracyclines, macrolides, clindamycin, chloramphenicol, streptogramins, & oxazolidinones

Chapter 45: Aminoglycosides & spectinomycin

Chapter 46: Sulfonamides, trimethoprim, & quinolones

Chapter 47: Antimycobacterial drugs

Chapter 48: Antifungal agents

Chapter 49: Antiviral agents

Chapter 50: Miscellaneous antimicrobial agents; disinfectants, antiseptics, & sterilants

Chapter 51: Clinical use of antimicrobial agents

Chapter 52: Antiprotozoal drugs

Chapter 53: Clinical pharmacology of the antihelminthic drugs

Chapter 54: Cancer chemotherapy

Chapter 55: Immunopharmacology

Section IX: Toxicology

Chapter 56: Introduction to toxicology: occupational & environmental

Chapter 57: Heavy metal intoxication & chelators

Chapter 58: Management of the poisoned patient

Section X: Special topics

Chapter 59: Special aspects of perinatal & pediatric pharmacology

Chapter 60: Special aspects of geriatric pharmacology

Chapter 61: Dermatologic pharmacology

Chapter 62: Drugs used in the treatment of gastrointestinal diseases

Chapter 63: Therapeutic & toxic potential of over-the-counter agents

Chapter 64: Dietary supplements & herbal medications

Chapter 65: Rational prescribing & prescription writing

Chapter 66: Important drug interactions & their mechanisms

Test Bank For Basic and Clinical Pharmacology 14th Edition by Bertram Katzung Chapter 1. Introduction: The Nature of Drugs & Drug Development & Regulation

1.	A nurse working in radiology administers iodine to a patient who is having a computed tomography (CT) scan. The nurse working on the oncology unit administers chemotherapy to patients who have cancer. At the Public Health Department, a nurse administers a measles-mumps-rubella (MMR) vaccine to a 14-month-old child as a routine immunization. Which branch of pharmacology best describes the actions of all three nurses?
A)	Pharmacoeconomics
B)	Pharmacotherapeutics
C)	Pharmacodynamics
D)	Pharmacokinetics
Ans:	В
	Feedback:
	Pharmacology is the study of the biologic effects of chemicals. Nurses are involved with clinical pharmacology or pharmacotherapeutics, which is a branch of pharmacology that deals with the uses of drugs to treat, prevent, and diagnose disease. The radiology nurse is administering a drug to help diagnose a disease. The oncology nurse is administering a drug to help treat a disease. Pharmacoeconomics includes any costs involved in drug therapy. Pharmacodynamics involves how a drug affects the body and pharmacokinetics is how the body acts on the body.
2.	A physician has ordered intramuscular (IM) injections of morphine, a narcotic, every 4 hours as needed for pain in a motor vehicle accident victim. The nurse is aware this drug has a high abuse potential. Under what category would morphine be classified?
A)	Schedule I

B) Schedule II

C)	Schedule III
D)	Schedule IV
Ans:	В
	Feedback:
	Narcotics with a high abuse potential are classified as Schedule II drugs because of severe dependence liability. Schedule I drugs have high abuse potential and no accepted medical use. Schedule III drugs have a lesser abuse potential than II and an accepted medical use. Schedule IV drugs have low abuse potential and limited dependence liability.
3.	When involved in phase III drug evaluation studies, what responsibilities

	would the nurse have?
A)	Working with animals who are given experimental drugs
B)	Choosing appropriate patients to be involved in the drug study
C)	Monitoring and observing patients closely for adverse effects
D)	Conducting research to determine effectiveness of the drug
Ans:	C

Feedback:

Phase III studies involve use of a drug in a vast clinical population in which patients are asked to record any symptoms they experience while taking the drugs. Nurses may be responsible for helping collect and analyze the information to be shared with the Food and Drug Administration (FDA) but would not conduct research independently because nurses do not prescribe medications. Use of animals in drug testing is done in the preclinical trials. Select patients who are involved in phase II studies to participate in studies where the participants have the disease the drug is intended to treat. These patients are monitored closely for drug action and adverse effects. Phase I studies involve healthy human volunteers who are usually paid for their participation. Nurses may observe for adverse effects and toxicity.

4.	What concept is considered when generic drugs are substituted for brand name drugs?
A)	Bioavailability

B)	Critical concentration
C)	Distribution
D)	Half-life
Ans:	А
	Feedback:
	Bioavailability is the portion of a dose of a drug that reaches the systemic circulation and is available to act on body cells. Binders used in a generic drug may not be the same as those used in the brand name drug. Therefore, the way the body breaks down and uses the drug may differ, which may eliminate a generic drug substitution. Critical concentration is the amount of a drug that is needed to cause a therapeutic effect and should not differ between generic and brand name medications. Distribution is the phase of pharmacokinetics, which involves the movement of a drug to the bodys tissues and is the same in generic and brand name drugs. A drugs half-life is the time it takes for the amount of drug to decrease to half the peak level, which should not change when substituting a generic medication.
5.	A nurse is assessing the patients home medication use. After listening to the patient list current medications, the nurse asks what priority question?
A)	Do you take any generic medications?

- B) Are any of these medications orphan drugs?
- C) Are these medications safe to take during pregnancy?
- D) Do you take any over-the-counter medications?

Ans: D

Feedback:

It is important for the nurse to specifically question use of over-the-counter medications because patients may not consider them important. The patient is unlikely to know the meaning of orphan drugs unless they too are health care providers. Safety during pregnancy, use of a generic medication, or classification of orphan drugs are things the patient would be unable to answer but could be found in reference books if the nurse wishes to research them.

6.	After completing a course on pharmacology for nurses, what will the nurse know?
A)	Everything necessary for safe and effective medication administration
B)	Current pharmacologic therapy; the nurse will not require ongoing education for 5 years.
C)	General drug information; the nurse can consult a drug guide for specific drug information.
D)	The drug actions that are associated with each classification of medication
Ans:	C
	Feedback:
	After completing a pharmacology course nurses will have general drug information needed for safe and effective medication administration but will need to consult a drug guide for specific drug information before administering any medication. Pharmacology is constantly changing, with new drugs entering the market and new uses for existing drugs identified. Continuing education in pharmacology is essential to safe practice. Nurses tend to become familiar with the medications they administer most often, but there will always be a need to research new drugs and also those the nurse is not familiar with because no nurse knows all medications.

7.	A nurse is instructing a pregnant patient concerning the potential risk to her fetus from a Pregnancy Category B drug. What would the nurse inform the patient?
A)	Adequate studies in pregnant women have demonstrated there is no risk to the fetus.
B)	Animal studies have not demonstrated a risk to the fetus, but there have been no adequate studies in pregnant women.
C)	Animal studies have shown an adverse effect on the fetus, but there are no adequate studies in pregnant women.
D)	There is evidence of human fetal risk, but the potential benefits from use of the drug may be acceptable despite potential risks.
Ans:	В